A Phase 3 interventional study of Eteplirsen in Muscular Dystrophy, Duchenne, sponsored by Sarepta Therapeutics, Inc.. Completed at 59 sites in 26 countries. Open to male participants aged 4 Years to 13 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one has the largest enrollment, is one of 2 that started in 2020, is one of 2 in phase 3, and was the 10th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →
eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 13 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 2
First in 2007; this study’s year is marked. 2 started in 2020.
This study's enrollment of 160 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 15 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc.: 5 open now, 6 under way, 2 of them phase 3. Of 21 finished, 15 (71%) have results posted.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 4th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 in phase 3, and was the 17th registered.
Sarepta Therapeutics, Inc.’s Muscular Dystrophy, Duchenne studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, from their registry updates:
Among Sarepta Therapeutics, Inc.’s 27 in Muscular Dystrophy, Duchenne:
This tab as a report to print or save as PDF → With an account.
Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram [mg/kg] and 200 mg/kg) of eteplirsen in approximately 10 participants with DMD; Part 2 (dose finding and dose comparison) will evaluate the efficacy and safety of the high doses (100 mg/kg and 200 mg/kg) of eteplirsen compared with that of the 30 mg/kg dose of eteplirsen, in approximately 144 participants with genetically confirmed deletion mutations amenable to treatment by skipping exon 51.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive eteplirsen 100 mg/kg once weekly for at least 4 weeks, followed by eteplirsen 200 mg/kg once weekly for at least 4 weeks.
Drug: Eteplirsen
Randomized participants will receive eteplirsen 30 mg/kg once weekly for up to 144 weeks.
Drug: Eteplirsen
Randomized participants will receive eteplirsen 100 mg/kg once weekly for up to 144 weeks.
Drug: Eteplirsen
Randomized participants will receive eteplirsen 200 mg/kg once weekly for up to 144 weeks.
Drug: Eteplirsen
Solution for intravenous (IV) infusion.
Also known as: AVI-4658, EXONDYS 51, EXONDYS
Part 1: Incidence of Adverse Events (AEs)
Time frame: Up to Week 148
Part 2: Change From Baseline at Week 144 in the NSAA Total Score (for Final Analysis)
Time frame: Baseline, Week 144
Part 2: Change from Baseline at Week 72 or Week 96 in NSAA Total Score (for Conditional Efficacy Interim Analysis)
Time frame: Baseline, Week 72 or Week 96
Part 2: Change From Baseline in Time to Rise From the Floor, Time to Complete 10-Meter Walk/Run, and the Timed Stair Ascend Test
Time frame: Baseline, Week 144
Part 2: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT)
Time frame: Baseline, Week 144
Part 2: Change from Baseline at Week 144 in Forced Vital Capacity Percent Predicted (FVC%p)
Time frame: Baseline, Week 144
Part 2: Time to Loss of Ambulation (LOA)
Time frame: Baseline up to Week 144
Part 2: Change From Baseline in Skeletal Muscle Dystrophin Expression
Time frame: Baseline, Postdose (at Week 24, Week 48, or Week 144)
Part 2: Incidence of Adverse Events (AEs)
Time frame: Baseline up to Week 148
Part 2: Pharmacokinetic (PK) Plasma Concentration of Eteplirsen
Time frame: 0 (predose) to 2 hours postdose up to Week 144
Ran from Jul 2020 to primary completion in Sep 2026, 73 months.
Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 73 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eteplirsen
Muscular Dystrophy, Duchenne →